Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
07/05/2024 | 02:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMGN | Amgen Inc |
03/05/2024 | 15:12 | IH Market News | Amgen, Bock Up; Cloudflare, Expedia Weak | NASDAQ:AMGN | Amgen Inc |
02/05/2024 | 22:01 | PR Newswire (US) | AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS | NASDAQ:AMGN | Amgen Inc |
01/05/2024 | 13:00 | PR Newswire (US) | AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 | NASDAQ:AMGN | Amgen Inc |
29/04/2024 | 22:00 | PR Newswire (US) | AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS | NASDAQ:AMGN | Amgen Inc |
26/04/2024 | 15:00 | PR Newswire (US) | AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY | NASDAQ:AMGN | Amgen Inc |
16/04/2024 | 23:26 | PR Newswire (US) | AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 | NASDAQ:AMGN | Amgen Inc |
09/03/2024 | 18:20 | PR Newswire (US) | AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024 | NASDAQ:AMGN | Amgen Inc |
06/03/2024 | 22:00 | PR Newswire (US) | AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND | NASDAQ:AMGN | Amgen Inc |
29/02/2024 | 22:00 | PR Newswire (US) | AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE | NASDAQ:AMGN | Amgen Inc |
26/02/2024 | 15:00 | PR Newswire (US) | AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO | NASDAQ:AMGN | Amgen Inc |
19/02/2024 | 22:00 | PR Newswire (US) | AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE | NASDAQ:AMGN | Amgen Inc |
14/02/2024 | 22:23 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:AMGN | Amgen Inc |
09/02/2024 | 22:00 | PR Newswire (US) | AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE | NASDAQ:AMGN | Amgen Inc |
07/02/2024 | 11:49 | IH Market News | Moody’s Downgrades NYCB to Junk Status, Ford Declares Special Dividend, and Other Market Updates | NASDAQ:AMGN | Amgen Inc |
06/02/2024 | 23:05 | IH Market News | U.S. Stocks Finish Choppy Trading Day Modestly Higher | NASDAQ:AMGN | Amgen Inc |
06/02/2024 | 22:20 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMGN | Amgen Inc |
06/02/2024 | 22:01 | PR Newswire (US) | AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS | NASDAQ:AMGN | Amgen Inc |
06/02/2024 | 12:27 | IH Market News | US Index Futures Mixed, Oil Prices Edge Higher | NASDAQ:AMGN | Amgen Inc |
02/02/2024 | 22:25 | IH Market News | U.S. Stocks Extend Thursday’s Rally On Upbeat Meta, Amazon Results | NASDAQ:AMGN | Amgen Inc |
01/02/2024 | 22:00 | PR Newswire (US) | AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS | NASDAQ:AMGN | Amgen Inc |
29/01/2024 | 11:00 | PR Newswire (Canada) | deCODE genetics: A sequence variant that increases risk of pregnancy loss | NASDAQ:AMGN | Amgen Inc |
17/01/2024 | 12:33 | IH Market News | Wall Street Highlights: Tesla Cuts Prices in Germany, Interactive Brokers Increases Revenue by 17%, and More | NASDAQ:AMGN | Amgen Inc |
10/01/2024 | 16:12 | Dow Jones News | Xeris Biopharma Shares Climb 12% on Amgen License Agreement | NASDAQ:AMGN | Amgen Inc |
10/01/2024 | 14:53 | Dow Jones News | Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment | NASDAQ:AMGN | Amgen Inc |
10/01/2024 | 14:45 | InvestorsHub NewsWire | GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons | NASDAQ:AMGN | Amgen Inc |
03/01/2024 | 22:00 | PR Newswire (US) | AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | NASDAQ:AMGN | Amgen Inc |
02/01/2024 | 17:42 | Dow Jones News | Amgen On Pace for Record High Close -- Data Talk | NASDAQ:AMGN | Amgen Inc |
26/12/2023 | 15:00 | PR Newswire (US) | AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) | NASDAQ:AMGN | Amgen Inc |
20/12/2023 | 02:38 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:AMGN | Amgen Inc |